BioStem Technologies, Inc. Chief Commercial Officer Barry Hassett filed a Form 4 on November 3, 2026, disclosing a transaction dated November 1, 2026, in which 253 shares of common stock were acquired through the vesting of restricted stock units at $0.00 per share.

Key Highlights

  • Transaction: Barry Hassett acquired 253 shares of BioStem Technologies common stock on November 1, 2026, via an RSU vesting event coded "M" at a price of $0.00.
  • Post-transaction ownership: Following the transaction, Hassett directly beneficially owned 5,256 shares of common stock.
  • RSU balance reduced: The RSU tranche associated with the vesting decreased from 1,519 to 1,266 units following the November 1, 2026, vesting.
  • Derivative holdings: Hassett also holds stock options totaling 84,329 underlying shares across three tranches, with exercise prices of $14.89, $14.89, and $5.50, respectively.
  • Additional RSU holdings: Two other RSU tranches of 4,497 units and 58,182 units remain outstanding and are directly owned.
  • Role: The reporting person is identified as Chief Commercial Officer of BioStem Technologies, Inc. (NASDAQ:BSEM).

Barry Hassett's November 2026 RSU Vesting at BioStem Technologies

According to the filing, Barry Hassett, Chief Commercial Officer of BioStem Technologies, Inc. (NASDAQ:BSEM), reported a single non-derivative transaction on November 1, 2026. The transaction code is "M," reflecting the acquisition of 253 shares of common stock through the settlement of restricted stock units at a price of $0.00. Following that transaction, the filing states Hassett directly beneficially owned 5,256 shares of common stock.

The RSU tranche associated with the vesting was described in the filing as vesting "33% on February 1, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period." After the November 1, 2026, vesting event, 1,266 restricted stock units from that tranche remain outstanding, according to the filing. Two additional RSU tranches were also reported: one with 4,497 units vesting in equal quarterly installments over four years from a December 9, 2024, grant date, and a second with 58,182 units scheduled to begin vesting on February 11, 2027.

The filing also discloses three option tranches, all directly held. The first covers 11,417 shares underlying stock options with an exercise price of $14.89 and an expiration of February 1, 2035. The second covers 2,427 shares at $14.89, expiring October 13, 2035. The third covers 70,485 shares at $5.50, expiring February 11, 2036. The filing was signed by Katherine Gorrell as Attorney-in-Fact on November 3, 2026.

What Was Disclosed

Barry Hassett, Chief Commercial Officer of BioStem Technologies, disclosed the vesting of 253 restricted stock units into common shares on November 1, 2026, at $0.00, bringing his direct common stock ownership to 5,256 shares, with multiple RSU and option tranches remaining outstanding.